# A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

> **NCT07694765** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **LaNova Medicines Limited** · enrollment: 90 (estimated)

## Conditions studied

- Malignant Tumors

## Interventions

- **DRUG:** LM-364 for injection
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07694765
- **Lead sponsor:** LaNova Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694765, "A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*